Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)

Clinical trial NCT04439305 · WITHDRAWN

Trial details

NCT number: NCT04439305
Sponsor: National Cancer Institute (NCI)
Status: WITHDRAWN
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Lymphoma Advanced Malignant Solid Neoplasm Hematopoietic and Lymphoid Cell Neoplasm Refractory Lymphoma Refractory Malignant Solid Neoplasm Refractory Plasma Cell Myeloma

Start date: 2016-02-25
Primary completion: 2018-06-07
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.